Assessing Step-Therapy Programs: A Step in the Right Direction

por Gleason, Patrick P.
Publicado 2007

Cholinesterase Inhibitor Utilization Patterns: Just Because It Can Be Counted Does Not Mean It Counts

por Starner, Catherine I., Gleason, Patrick P.
Publicado 2008

Drug super spender tsunami: An integrated medical and pharmacy benefits assessment

por Starner, Catherine I, Bowen, Kevin, Gleason, Patrick P
Publicado 2022

Formulary Review of 2 New Biologic Agents: Tocilizumab for Rheumatoid Arthritis and Ustekinumab for Plaque Psoriasis

por Schafer, Jeremy A., Kjesbo, Nicole K., Gleason, Patrick P.
Publicado 2010

Price Increases and New Drugs Drive Increased Expenditures for Multiple Sclerosis

por Schafer, Jeremy A., Gunderson, Brent W., Gleason, Patrick P.
Publicado 2010

Real-world outcomes and direct care cost before and after elexacaftor/tezacaftor/ivacaftor initiation in commercially insured members with cystic fibrosis

por Marshall, Landon Z, Espinosa, Rachel, Starner, Catherine I, Gleason, Patrick P
Publicado 2023

Association of a Controlled Substance Scoring Algorithm with Health Care Costs and Hospitalizations: A Cohort Study

por Starner, Catherine I., Qiu, Yang, Karaca-Mandic, Pinar, Gleason, Patrick P.
Publicado 2016

Pharmacy Students' Views of Managed Care Pharmacy and PBMs: Should There Be More Exposure to Managed Care in the Pharmacy Curriculum?

por Pittenger, Amy L., Starner, Catherine I., Thompson, Kaj, Gleason, Patrick P.
Publicado 2010

Telithromycin: The Perils of Hasty Adoption and Persistence of Off-Label Prescribing

por Gleason, Patrick P., Walters, Carol, Heaton, Alan H., Schafer, Jeremy A.
Publicado 2007

Rosiglitazone Prior Authorization Safety Policy: A Cohort Study

por Starner, Catherine I., Fenrick, Beckie, Coleman, John, Wickersham, Peter, Gleason, Patrick P.
Publicado 2012

Rosiglitazone and Pioglitazone Utilization from January 2007 Through May 2008 Associated With Five Risk-Warning Events

por Starner, Catherine I., Schafer, Jeremy A., Heaton, Alan H., Gleason, Patrick P.
Publicado 2008

Dalfampridine Prior Authorization Program: A Cohort Study

por Gleason, Patrick P., Phillips, Jill, Fenrick, Beckie A., Delgado-Riley, Ana, Starner, Catherine I.
Publicado 2013

Utilization, Cost Trends, and Member Cost - Share for Self-Injectable Multiple Sclerosis Drugs-Pharmacy and Medical Benefit Spending From 2004 Through 2007

por Kunze, April M., Gunderson, Brent W., Gleason, Patrick P., Heaton, Alan H., Johnson, Steven V.
Publicado 2007

Medical Costs and Health Care Utilization Among Self-Insured Members with Carve-In Versus Carve-Out Pharmacy Benefits

por Smith, Julia J., Qiu, Yang, Lam, Steve V., Lockwood, Chondra M., Pegus, Cheryl, Gleason, Patrick P.
Publicado 2020

Generic Drug Discount Programs: Are Prescriptions Being Submitted for Pharmacy Benefit Adjudication?

por Tungol, Alexandra, Starner, Catherine I., Gunderson, Brent W., Schafer, Jeremy A., Qiu, Yang, Gleason, Patrick P.
Publicado 2012

Relationship of the Magnitude of Member Cost-Share and Medication Persistence With Newly Initiated Renin Angiotensin System Blockers

por Zhang, Dongmu, Carson, Angeline M., Gleason, Patrick P., Schondelmeyer, Stephen W., Schommer, Jon C., Dowd, Bryan E., Heaton, Alan H.
Publicado 2007

Health Plan Utilization and Costs of Specialty Drugs Within 4 Chronic Conditions

por Gleason, Patrick P., Alexander, G. Caleb, Starner, Catherine I., Ritter, Stephen T., Van Houten, Holly K., Gunderson, Brent W., Shah, Nilay D.
Publicado 2013